Suzanne L Topalian

Suzanne L Topalian

UNVERIFIED PROFILE

Are you Suzanne L Topalian?   Register this Author

Register author
Suzanne L Topalian

Suzanne L Topalian

Publications by authors named "Suzanne L Topalian"

Are you Suzanne L Topalian?   Register this Author

81Publications

4498Reads

12Profile Views

Mechanisms regulating PD-L1 expression on tumor and immune cells.

J Immunother Cancer 2019 Nov 15;7(1):305. Epub 2019 Nov 15.

Department of Surgery, Johns Hopkins University School of Medicine, Sidney Kimmel Comprehensive Cancer Center, and Bloomberg~Kimmel Institute for Cancer Immunotherapy, Baltimore, MD, 21287, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40425-019-0770-2DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6858680PMC
November 2019

Merkel cell polyomavirus-specific immune responses in patients with Merkel cell carcinoma receiving anti-PD-1 therapy.

J Immunother Cancer 2018 11 27;6(1):131. Epub 2018 Nov 27.

Department of Medicine, Divisions of Dermatology and Medical Oncology, University of Washington, 850 Republican Street, Seattle, WA, 98109, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40425-018-0450-7DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6258401PMC
November 2018

Neoadjuvant PD-1 Blockade in Resectable Lung Cancer.

N Engl J Med 2018 May 16;378(21):1976-1986. Epub 2018 Apr 16.

From the Bloomberg-Kimmel Institute for Cancer Immunotherapy and the Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore (P.M.F., K.N.S., V.A., T.R.C., M.Z., S.C.Y., S.B., R.J.B., J.N., K.A.M., F.V., H.G., J.Z., J.X.C., H.Y.C., J.-W.S., R.B.S., J.W., E.G., H.W., G.L.R., J.M.T., V.E.V., S.L.T., J.R.B., D.M.P.); Memorial Sloan Kettering Cancer Center and Weill Cornell Medicine (J.E.C., M.D.H., D.R.J., M.J.V., N.R., Z.O., V.R., J.D.W., T.M.) and the Ludwig Collaborative (J.D.W., T.M.) - all in New York; the Parker Institute for Cancer Immunotherapy, San Francisco (J.D.W., T.M.); and Swim Across America Laboratory, Charlotte, NC (J.D.W., T.M.).

View Article

Download full-text PDF

Source
http://www.nejm.org/doi/10.1056/NEJMoa1716078
Publisher Site
http://dx.doi.org/10.1056/NEJMoa1716078DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6223617PMC
May 2018

Targeting Immune Checkpoints in Cancer Therapy.

JAMA 2017 Nov;318(17):1647-1648

Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, Maryland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/jama.2017.14155DOI Listing
November 2017

Association of HIV Status With Local Immune Response to Anal Squamous Cell Carcinoma: Implications for Immunotherapy.

JAMA Oncol 2017 Jul;3(7):974-978

Department of Dermatology, Johns Hopkins University School of Medicine, Sidney Kimmel Comprehensive Cancer Center and Bloomberg~Kimmel Institute for Cancer Immunotherapy, Baltimore, Maryland3Department of Pathology, Johns Hopkins University School of Medicine, Sidney Kimmel Comprehensive Cancer Center and Bloomberg~Kimmel Institute for Cancer Immunotherapy, Baltimore, Maryland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/jamaoncol.2017.0115DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5696632PMC
July 2017

Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma.

J Clin Oncol 2017 Mar 14;35(7):785-792. Epub 2016 Nov 14.

Jeffrey S. Weber, H. Lee Moffitt Cancer Center, Tampa, FL; F. Stephen Hodi, Dana-Farber Cancer Institute, Boston, MA; Jedd D. Wolchok, Memorial Sloan Kettering Cancer Center, New York, NY; Suzanne L. Topalian, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD; Mario Sznol, Yale University School of Medicine and Smilow Cancer Center, Yale-New Haven Hospital, New Haven, CT; Hewei Li, Ian M. Waxman, and Joel Jiang, Bristol-Myers Squibb, Princeton, NJ; Dirk Schadendorf, University of Essen, Essen, Germany; James Larkin, Royal Marsden National Health Service Foundation Trust, London, United Kingdom; Georgina V. Long, Melanoma Institute Australia and University of Sydney, Sydney, New South Wales, Australia; and Caroline Robert, Gustave Roussy and Paris-Sud University, Villejuif-Paris Sud, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.66.1389DOI Listing
March 2017

PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma.

N Engl J Med 2016 Jun 19;374(26):2542-52. Epub 2016 Apr 19.

From the University of Washington Medical Center (P.T.N., S. Bhatia, N.J.M., E.M.S., M.M.S., J.A.T., M.A.C.), Fred Hutchinson Cancer Research Center (P.T.N., S. Bhatia, S.P.F., L.L., J.A.T., M.A.C.), Cancer Immunotherapy Trials Network (S.P.F., L.L., M.A.C.), and Cancer Research and Biostatistics (A.M., L.R.S.) - all in Seattle; Johns Hopkins University School of Medicine and Kimmel Cancer Center, Baltimore (E.J.L., S. Berry, D.M.P., W.H.S., J.C.S., J.M.T., S.L.T.), and Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda. (E.S.) - both in Maryland; Winship Cancer Institute of Emory University, Atlanta (R.R.K.); Merck Research Laboratories, Kenilworth, NJ (L.A., E.K.C., S.M.T., J.H.Y.); University of California, San Francisco, San Francisco (A.D.), and Stanford University, Stanford (H.E.K., K.M., S.A.R.) - both in California; Mt. Sinai Medical Center, New York (P.A.F.); Yale University, New Haven, CT (H.M.K.); and Ohio State University, Columbus (T.O.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1603702DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4927341PMC
June 2016

Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy.

Nat Rev Cancer 2016 05 15;16(5):275-87. Epub 2016 Apr 15.

Department of Oncology, Johns Hopkins University School of Medicine, Sidney Kimmel Comprehensive Cancer Center and Bloomberg-Kimmel Institute for Cancer Immunotherapy, 1550 Orleans Street, CRB2 Room 508, Baltimore, Maryland 21287, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nrc.2016.36DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5381938PMC
May 2016

Antagonists of PD-1 and PD-L1 in Cancer Treatment.

Semin Oncol 2015 Aug 10;42(4):587-600. Epub 2015 Jun 10.

Department of Surgery, The Johns Hopkins University School of Medicine and Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1053/j.seminoncol.2015.05.013DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4555873PMC
August 2015

Survival, Durable Response, and Long-Term Safety in Patients With Previously Treated Advanced Renal Cell Carcinoma Receiving Nivolumab.

J Clin Oncol 2015 Jun 30;33(18):2013-20. Epub 2015 Mar 30.

David F. McDermott, Beth Israel Deaconess Medical Center; Toni K. Choueiri, Dana-Farber Cancer Institute/Brigham and Women's Hospital; Igor Puzanov and F. Stephen Hodi, Dana-Farber Cancer Institute, Boston, MA; Charles G. Drake, Julie R. Brahmer, Hans J. Hammers, Suzanne L. Topalian, and Drew M. Pardoll, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins, Baltimore, MD; Mario Sznol, Yale University School of Medicine and Smilow Cancer Center, Yale-New Haven Hospital, New Haven, CT; John D. Powderly, Carolina BioOncology Institute, Huntersville, NC; David C. Smith, University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; Richard D. Carvajal, Memorial Sloan-Kettering Cancer Center, New York, NY; Jon M. Wigginton, Georgia D. Kollia, Ashok Gupta, Dan McDonald, and Vindira Sankar, Bristol-Myers Squibb, Princeton, NJ; Jeffrey A. Sosman, Vanderbilt-Ingram Cancer Center, Nashville, TN; and Michael B. Atkins, Georgetown-Lombardi Comprehensive Cancer Center, Washington, DC.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2014.58.1041DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4517051PMC
June 2015

Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer.

J Clin Oncol 2015 Jun 20;33(18):2004-12. Epub 2015 Apr 20.

Scott N. Gettinger and Mario Sznol, Yale Cancer Center, New Haven, CT; Leora Horn, David P. Carbone, and Jeffrey A. Sosman, Vanderbilt University Medical Center; David R. Spigel, Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN; Leena Gandhi, David M. Jackman, and F. Stephen Hodi, Dana-Farber Cancer Institute; Rebecca S. Heist and Lecia V. Sequist, Massachusetts General Hospital Cancer Center; David F. McDermott, Beth Israel Deaconess Medical Center, Boston, MA; Scott J. Antonia and Mary C. Pinder-Schenck, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL; Naiyer A. Rizvi, Richard D. Carvajal, and Matthew D. Hellmann, Memorial Sloan Kettering Cancer Center, New York, NY; John D. Powderly, Carolina BioOncology Institute, Huntersville, NC; David C. Smith, University of Michigan, Ann Arbor, MI; Philip Leming, Christ Hospital Cancer Center, Cincinnati, OH; Suzanne L. Topalian, Drew M. Pardoll, and Julie R. Brahmer, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins, Baltimore, MD; and Vindira Sankar, Christoph M. Ahlers, Mark Salvati, Jon M. Wigginton, Georgia D. Kollia, and Ashok K. Gupta, Bristol-Myers Squibb, Princeton, NJ.

View Article

Download full-text PDF

Source
http://jco.ascopubs.org/content/early/2015/04/15/JCO.2014.58
Web Search
http://jco.ascopubs.org/cgi/doi/10.1200/JCO.2014.58.3708
Publisher Site
http://dx.doi.org/10.1200/JCO.2014.58.3708DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4672027PMC
June 2015

Immune checkpoint blockade: a common denominator approach to cancer therapy.

Cancer Cell 2015 Apr 6;27(4):450-61. Epub 2015 Apr 6.

Department of Oncology, Sidney Kimmel Comprehensive Cancer Center and Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15356108150008
Publisher Site
http://dx.doi.org/10.1016/j.ccell.2015.03.001DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4400238PMC
April 2015

PD-L1 expression in melanocytic lesions does not correlate with the BRAF V600E mutation.

Cancer Immunol Res 2015 Feb 4;3(2):110-5. Epub 2014 Nov 4.

Department of Pathology, The Johns Hopkins University School of Medicine and Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland. Department of Dermatology, The Johns Hopkins University School of Medicine and Sidney Kimmel Comprehensive Cancer Center, Baltimore, Baltimore, Maryland. Department of Oncology, The Johns Hopkins University School of Medicine and Sidney Kimmel Comprehensive Cancer Center, Baltimore, Baltimore, Maryland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/2326-6066.CIR-14-0145DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4324161PMC
February 2015

Circulating tumor DNA analysis as a real-time method for monitoring tumor burden in melanoma patients undergoing treatment with immune checkpoint blockade.

J Immunother Cancer 2014 16;2(1):42. Epub 2014 Dec 16.

Department of Oncology, Johns Hopkins University School of Medicine and Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD USA ; Ludwig Center for Cancer Genetics and Therapeutics and the Swim Across America Laboratory, Johns Hopkins University School of Medicine and Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40425-014-0042-0DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4267741PMC
December 2014

Balance and imbalance in the immune system: life on the edge.

Immunity 2014 Nov 20;41(5):682-4. Epub 2014 Nov 20.

Department of Microbiology and Immunobiology, Harvard Medical School, Boston, MA 02115, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.immuni.2014.11.005DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4710093PMC
November 2014

Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab.

J Clin Oncol 2014 Apr 3;32(10):1020-30. Epub 2014 Mar 3.

Suzanne L. Topalian, William H. Sharfman, Julie R. Brahmer, Evan J. Lipson, Janis M. Taube, and Drew M. Pardoll, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD; Mario Sznol and Harriet M. Kluger, Yale University School of Medicine and Smilow Cancer Center, Yale-New Haven Hospital, New Haven, CT; David F. McDermott, Beth Israel Deaconess Medical Center; Donald P. Lawrence, Massachusetts General Hospital Cancer Center; F. Stephen Hodi, Dana-Farber Cancer Institute, Boston, MA; Richard D. Carvajal, Memorial Sloan-Kettering Cancer Center, New York, NY; Michael B. Atkins, Georgetown-Lombardi Comprehensive Cancer Center, Washington, DC; John D. Powderly, Carolina BioOncology Institute, Huntersville, NC; Philip D. Leming, The Christ Hospital Cancer Center, Cincinnati, OH; Igor Puzanov and Jeffrey A. Sosman, Vanderbilt University Medical Center, Nashville, TN; David C. Smith, University of Michigan, Ann Arbor, MI; and Jon M. Wigginton, Georgia D. Kollia, and Ashok Gupta, Bristol-Myers Squibb, Princeton, NJ.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2013.53.0105DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4811023PMC
April 2014

Structure-based design of altered MHC class II-restricted peptide ligands with heterogeneous immunogenicity.

J Immunol 2013 Nov 9;191(10):5097-106. Epub 2013 Oct 9.

Department of Surgery, Johns Hopkins University School of Medicine and the Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD 21287;

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4049/jimmunol.1300467DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3888030PMC
November 2013

Durable cancer regression off-treatment and effective reinduction therapy with an anti-PD-1 antibody.

Clin Cancer Res 2013 Jan 20;19(2):462-8. Epub 2012 Nov 20.

Department of Oncology, Johns Hopkins University School of Medicine and Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD 21287, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-12-2625DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3548952PMC
January 2013

Structural insights into the editing of germ-line-encoded interactions between T-cell receptor and MHC class II by Vα CDR3.

Proc Natl Acad Sci U S A 2012 Sep 28;109(37):14960-5. Epub 2012 Aug 28.

W. M. Keck Laboratory for Structural Biology, University of Maryland Institute for Bioscience and Biotechnology Research, Rockville, MD 20850, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1073/pnas.1207186109DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3443186PMC
September 2012

Workshop on immunotherapy combinations. Society for Immunotherapy of Cancer annual meeting Bethesda, November 3, 2011.

J Transl Med 2012 May 28;10:108. Epub 2012 May 28.

Centro de Investigacion Medica Aplicada, Universidad de Navarra, Avda Pio XII, 55, 31008 Pamplona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/1479-5876-10-108DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3404934PMC
May 2012

Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity.

Curr Opin Immunol 2012 Apr 9;24(2):207-12. Epub 2012 Jan 9.

Department of Surgery, Johns Hopkins University School of Medicine and Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD 21287, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.coi.2011.12.009DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3319479PMC
April 2012

Translating research into therapies.

Cell 2012 Mar;148(6):1077-8

Weill Cornell Medical College, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cell.2012.02.036DOI Listing
March 2012

Cancer immunotherapy comes of age.

J Clin Oncol 2011 Dec 31;29(36):4828-36. Epub 2011 Oct 31.

Johns Hopkins University School of Medicine and Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2011.38.0899DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3255990PMC
December 2011

Control of T(H)17/T(reg) balance by hypoxia-inducible factor 1.

Cell 2011 Sep 25;146(5):772-84. Epub 2011 Aug 25.

Immunology and Hematopoiesis Division, Department of Oncology and Medicine, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Maryland 21231, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cell.2011.07.033DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3387678PMC
September 2011

Phase 2 trial of single agent Ipilimumab (anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma.

J Immunother 2010 Oct;33(8):828-33

Surgery Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CJI.0b013e3181eec14cDOI Listing
October 2010

Structural basis for the presentation of tumor-associated MHC class II-restricted phosphopeptides to CD4+ T cells.

J Mol Biol 2010 Jun 24;399(4):596-603. Epub 2010 Apr 24.

University of Maryland Institute for Bioscience and Biotechnology Research, W. M. Keck Laboratory for Structural Biology, Rockville, MD 20850, USA.

View Article

Download full-text PDF

Source
http://linkinghub.elsevier.com/retrieve/pii/S002228361000411
Publisher Site
http://dx.doi.org/10.1016/j.jmb.2010.04.037DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2904831PMC
June 2010

Nonsynonymous somatic mitochondrial mutations occur in the majority of cutaneous melanomas.

Melanoma Res 2008 Jun;18(3):214-9

Department of Surgery, Division of Plastic and Reconstructive Surgery, Johns Hopkins Medical Institutions, Baltimore, Maryland, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CMR.0b013e3282f88a56DOI Listing
June 2008

Structural basis for the recognition of mutant self by a tumor-specific, MHC class II-restricted T cell receptor.

Nat Immunol 2007 Apr 4;8(4):398-408. Epub 2007 Mar 4.

Center for Advanced Research in Biotechnology, WM Keck Laboratory for Structural Biology, University of Maryland Biotechnology Institute, Rockville, Maryland 20850, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/ni1447DOI Listing
April 2007

Immunization of HLA-A*0201 and/or HLA-DPbeta1*04 patients with metastatic melanoma using epitopes from the NY-ESO-1 antigen.

J Immunother 2004 Nov-Dec;27(6):472-7

Surgery Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892-1502, USA.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2227905PMC
http://dx.doi.org/10.1097/00002371-200411000-00007DOI Listing
April 2005

Cell transfer therapy for cancer: lessons from sequential treatments of a patient with metastatic melanoma.

J Immunother 2003 Sep-Oct;26(5):385-93

Center for Cancer Research, Surgery Branch, National Cancer Institute, National Institute of Health, Building 10, Room 2B42, 10 Center Drive, Bethesda, Maryland 20892, USA.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1764125PMC
http://dx.doi.org/10.1097/00002371-200309000-00001DOI Listing
April 2004

Lentivirus vector-mediated expression of tumor-associated epitopes by human antigen presenting cells.

Hum Gene Ther 2004 Apr;15(4):393-404

Surgery Branch, National Cancer Institute, Center for Cancer Research, National Institutes of Health, Bethesda, MD 20892, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1089/104303404322959542DOI Listing
April 2004

CD4(+) T-cell recognition of mutated B-RAF in melanoma patients harboring the V599E mutation.

Cancer Res 2004 Mar;64(5):1595-9

Surgery Branch, National Cancer Institute, Center for Cancer Research, NIH, Bethesda, MD 20892, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.can-03-3231DOI Listing
March 2004

Selection of appropriate control genes to assess expression of tumor antigens using real-time RT-PCR.

Biotechniques 2004 Jan;36(1):84-6, 88, 90-1

National Institutes of Health, Bethesda, MD, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2144/04361ST04DOI Listing
January 2004

Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer.

J Clin Oncol 2003 Aug;21(16):3127-32

Surgery Branch, Biostatistics and Data Management Section, Department of Pathology, National Cancer Institute/NIH, Room 2B-37, Building 10, 9000 Rockville Pike, Bethesda, MD 20892, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2003.02.122DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2275327PMC
August 2003

Revelation of a cryptic major histocompatibility complex class II-restricted tumor epitope in a novel RNA-processing enzyme.

Cancer Res 2002 Oct;62(19):5505-9

Surgery Branch, National Cancer Institute, Center for Cancer Research, NIH, Bethesda, Maryland 20892-1502, USA.

View Article

Download full-text PDF

Source
October 2002